Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07148947 · ClinicalTrials.gov registry record · Phase 2
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
A Phase 2 study of Accelerated Phase Myeloproliferative Neoplasm and Blast Phase Myeloproliferative Neoplasm, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT07148947 is a Phase 2 study of Accelerated Phase Myeloproliferative Neoplasm and Blast Phase Myeloproliferative Neoplasm that is actively recruiting participants, run by University of Washington. The registered enrollment target is 27 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07148947, a Phase 2 study of Accelerated Phase Myeloproliferative Neoplasm and Blast Phase Myeloproliferative Neoplasm, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests if adding pacritinib to standard of care azacitidine or decitabine increases the number of patients able to proceed to hematopoietic stem cell transplantation (bridging) for patients with accelerated and blast phase myeloproliferative neoplasms. Pacritinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Azacitidine and decitabine are in a class of medications called hypomethylation agents. They work by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Adding pacritinib to standard of care azacitidine or decitabine may increase the number of patients able to proceed to hematopoietic stem cell transplantation for patients with accelerated and blast phase myeloproliferative neoplasms.
Conditions Studied
Interventions
- DRUG Azacitidine
- DRUG Decitabine
- OTHER Survey Administration
- DRUG Decitabine and Cedazuridine
- DRUG Pacritinib
Study Locations (1)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2026-03-02 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07148947
The ClinicalTrials.gov registry entry for NCT07148947 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Accelerated Phase Myeloproliferative Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Azacitidine is the first listed.
NCT07148947 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT07148947 about?
NCT07148947 is a clinical study titled "Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms". This phase II trial tests if adding pacritinib to standard of care azacitidine or decitabine increases the number of patients able to proceed to hematopoietic stem cell transplantation (bridging) for patients with accelerated and blast phase myeloproliferative neoplasms. Pacritinib may stop the grow...
What is the current status of trial NCT07148947?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2026-03-02. Estimated completion is 2028-12-31.
What conditions does trial NCT07148947 study?
This clinical trial studies the following conditions: Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm.
What interventions are being tested in trial NCT07148947?
The interventions under investigation include: Azacitidine (DRUG), Decitabine (DRUG), Survey Administration (OTHER), Decitabine and Cedazuridine (DRUG), Pacritinib (DRUG).
Who is sponsoring clinical trial NCT07148947?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07148947 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Accelerated Phase Myeloproliferative Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Accelerated Phase Myeloproliferative Neoplasm
All registered trials for this condition
Blast Phase Myeloproliferative Neoplasm
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.